Variables | Values | Univariate | Â | Multivariate | Â |
---|---|---|---|---|---|
Hazard Ratio (95% CI) | P-value | Hazard Ratio (95% CI) | P-value | ||
Clinicopathological factors | |||||
 Age (years) | < 65 vs. ≥65 | 1.45 (0.91–2.33) | 0.121 | 0.96 (0.56–1.65) | 0.880 |
 Gender | Male vs. Female | 1.51 (0.93–2.45) | 0.096 | 1.55 (0.86–2.78) | 0.144 |
 ECOG-PS | 0–1 vs. 2 | 2.67 (1.44–4.92) | 0.002 | 2.61 (1.26–5.44) | 0.010 |
 BMI (kg/m2) | < 23 vs. ≥23 | 0.70 (0.44–1.11) | 0.127 |  |  |
 Tumor Type | HCC vs. BTC or cHCC-CC | 2.50 (1.49–4.19) | 0.001 | 2.18 (1.15–4.15) | 0.018 |
 Previous anticancer therapy | Yes vs. No | 1.77 (1.08–2.89) | 0.023 | 1.01 (0.53–1.90) | 0.980 |
  Prior surgery | Yes vs. No | 0.77 (0.49–1.21) | 0.250 |  |  |
  Prior chemotherapy | No vs. Yes | 1.31 (0.82–2.08) | 0.260 |  |  |
  Prior radiotherapy | No vs. Yes | 1.12 (0.62–2.00) | 0.710 |  |  |
Biochemical factors | |||||
 Ferritin (ng/mL) | Lowa vs. Highb | 2.47 (1.54–3.96) | < 0.001 | 1.96 (1.03–3.73) | 0.041 |
 Hb (g/dL) | Highc vs. Lowd | 2.24 (1.35–3.73) | 0.002 | 1.50 (0.81–2.79) | 0.200 |
 Total bilirubin (mg/dL) | ≤1.2 vs. > 1.2 | 2.44 (1.37–4.35) | 0.002 | 2.02 (1.00–4.07) | 0.051 |
 AST (IU/L) | < 40 vs. ≥40 | 1.56 (0.99–2.47) | 0.058 |  |  |
 ALT (IU/L) | < 40 vs. ≥40 | 0.85 (0.53–1.36) | 0.500 |  |  |
 γ-GT (IU/L) | ≤66 vs. > 66 | 1.98 (1.20–3.25) | 0.007 | 0.91 (0.46–1.80) | 0.790 |
 PT INR | ≤1.16 vs. > 1.16 | 1.33 (0.81–2.19) | 0.260 |  |  |
 Albumin (g/dL) | ≥3.5 vs. < 3.5 | 2.16 (1.18–3.98) | 0.013 | 1.64 (0.77–3.49) | 0.198 |
 WBC (×103/μL) | < 10.0 vs. ≥10.0 | 2.98 (1.49–5.98) | 0.002 | 1.80 (0.79–4.11) | 0.165 |
 CRP (mg/L) | < 10.0 vs. ≥10.0 | 3.23 (1.99–5.25) | < 0.001 | 2.12 (1.20–3.76) | 0.010 |